ATE426024T1 - C-c chemokin rezeptor 3: ckr-3 oder eos-l2 - Google Patents

C-c chemokin rezeptor 3: ckr-3 oder eos-l2

Info

Publication number
ATE426024T1
ATE426024T1 AT96907010T AT96907010T ATE426024T1 AT E426024 T1 ATE426024 T1 AT E426024T1 AT 96907010 T AT96907010 T AT 96907010T AT 96907010 T AT96907010 T AT 96907010T AT E426024 T1 ATE426024 T1 AT E426024T1
Authority
AT
Austria
Prior art keywords
ckr
eos
recombinant
chemokine receptor
polypeptides
Prior art date
Application number
AT96907010T
Other languages
English (en)
Inventor
Craig Gerard
Norma Gerard
Charles Mackay
Paul Ponath
Theodore Post
Shixin Qin
Original Assignee
Millennium Pharm Inc
Brigham & Womens Hospital
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23479910&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE426024(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc, Brigham & Womens Hospital, Childrens Medical Center filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE426024T1 publication Critical patent/ATE426024T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96907010T 1995-01-19 1996-01-19 C-c chemokin rezeptor 3: ckr-3 oder eos-l2 ATE426024T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/375,199 US6806061B1 (en) 1995-01-19 1995-01-19 G protein-coupled receptor gene and methods of use therefor

Publications (1)

Publication Number Publication Date
ATE426024T1 true ATE426024T1 (de) 2009-04-15

Family

ID=23479910

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96907010T ATE426024T1 (de) 1995-01-19 1996-01-19 C-c chemokin rezeptor 3: ckr-3 oder eos-l2

Country Status (10)

Country Link
US (1) US6806061B1 (de)
EP (1) EP0828828B1 (de)
JP (1) JPH10512753A (de)
KR (1) KR19980701570A (de)
AT (1) ATE426024T1 (de)
AU (1) AU688206B2 (de)
CA (1) CA2207086A1 (de)
DE (1) DE69637874D1 (de)
ES (1) ES2324502T3 (de)
WO (1) WO1996022371A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6806061B1 (en) * 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
US6537764B1 (en) 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
CA2252850A1 (en) * 1996-04-26 1997-11-06 Merck & Co., Inc. Eosinophil eotaxin receptor
US6271347B1 (en) 1996-04-26 2001-08-07 Merck & Co., Inc. Eosinophil eotaxin receptor
ES2288305T3 (es) * 1996-09-10 2008-01-01 Theodor-Kocher Institute Receptor de quimiocinas cxcr3, anticuerpos, acidos nucleicos y metodos de uso.
AU6132698A (en) * 1997-01-23 1998-08-18 Schering Corporation Mammalian chemokines; receptors; reagents; uses
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6204024B1 (en) 1997-09-12 2001-03-20 Akzo Nobel N.V. CCR5 RNA transcription based amplification assay
US6110695A (en) * 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
CA2235420A1 (en) 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6670149B1 (en) 1999-03-01 2003-12-30 Millennium Pharmaceuticals, Inc. TWIK-5 potassium channel nucleic acids and uses therefor
US6664373B1 (en) 1999-03-01 2003-12-16 Millennium Pharmaceuticals, Inc. TWIK-5 potassium channel polypeptides and uses therefor
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
GB0013345D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Modified receptor and assay
AU2001286519A1 (en) 2000-08-15 2002-02-25 Millennium Pharmaceuticals, Inc. Method for identifying modulators of "mec"-induced functions of ccr3 and/or ccr10
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
CA2456928A1 (en) * 2001-08-10 2003-02-20 Topigen Pharmaceutique Inc. Cellular virus receptors and methods of use
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
WO2005106492A2 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
CA2584457C (en) * 2004-10-29 2012-10-23 Topigen Pharmaceuticals Inc. Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010138591A1 (en) 2009-05-26 2010-12-02 University Of Kentucky Research Foundation Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5462856A (en) 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
US5453491A (en) 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
US5543503A (en) 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US5668006A (en) 1992-07-17 1997-09-16 American Cyanamid Company Somatostatin receptors
US5508384A (en) 1992-09-10 1996-04-16 New York University Polypeptide derived from a popamine receptor, and compositions and methods thereof
DE69333885T2 (de) 1992-11-10 2006-09-14 Genentech, Inc., South San Francisco C-c ckr-1, ein c-c chemokin rezeptor
JPH07503145A (ja) 1992-11-17 1995-04-06 イコス　コーポレイション 新規の７−トランスメンブランレセプター
US5652133A (en) 1993-01-28 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloning and expression of the human macrophage inflammatory protein-1.alpha.α) /rantes receptor
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
DE4332256C1 (de) 1993-09-22 1995-03-09 Lipp Martin Dr Dr Habil Monoklonale Antikörper gegen Leukozyten-spezifische G-Protein-gekoppelte Rezeptoren
US6806061B1 (en) * 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C

Also Published As

Publication number Publication date
CA2207086A1 (en) 1996-07-25
EP0828828B1 (de) 2009-03-18
WO1996022371A2 (en) 1996-07-25
JPH10512753A (ja) 1998-12-08
US6806061B1 (en) 2004-10-19
ES2324502T3 (es) 2009-08-07
WO1996022371A3 (en) 1996-10-17
EP0828828A2 (de) 1998-03-18
AU688206B2 (en) 1998-03-05
AU5020296A (en) 1996-08-07
KR19980701570A (de) 1998-05-15
DE69637874D1 (de) 2009-04-30

Similar Documents

Publication Publication Date Title
DE69637874D1 (de) C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2
LU90591I2 (fr) Enbrel-etanercept
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
BR9813608A (pt) Polipeptìdeo isolado, sequências de ácido nucleico isolado e mutante, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, processos para produzir uma sequência de ácido nucleico mutante, para produzir um polipeptìdeo, para produzir um mutante de uma célula originária e para produzir uma proteìna, e, célula mutante
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
DE69738514D1 (de) Verbesserte expressionsvektoren
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
EP1717315A3 (de) Osteoprotegerin bindende Proteine und Rezeptoren
WO1995009872B1 (en) Dna encoding prostaglandin receptor ip
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
AR016436A1 (es) Proteina que inhibe a la p27, adn que la codifica, anticuerpos y productos de disociacion de los mismos, acido nucleico antisentido, estructura artificialde acido nucleico y la utilizacion de todo esto en terapia y profilaxis de enfermedades
KR940021579A (ko) 골(骨)-관련 전사 조절인자형 단백질 및 이의 제조방법
AUPN154295A0 (en) Nucleic acid molecule encoding a protein with avian gamma-interferon activity
CA2032167A1 (en) Dna coding for protein binds to enhancer of.alpha.-fetoprotein gene
Sarvas et al. A precursor form of the penicillinase from Bacillus licheniformis
ATE302214T1 (de) Enamel-matrix bezogene polypeptide
EP0811685A3 (de) Menschliche Rezeptoren für den von Blutplättchen abstammenden Wachstumsfaktor
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
WO1997008317A3 (en) Human hypothalmic ('hr') receptor polypeptide compositions, methods and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties